In a clinical trial (NCT03156101) evaluating TCR-T cell therapy targeting the CD19 molecule, the ORR was 77% in patients with ALL and non-Hodgkin’s lymphoma. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.